Initial testing of aplidin by the pediatric pre-clinical testing program
نویسندگان
چکیده
منابع مشابه
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program.
Rapamycin demonstrated broad-spectrum tumor growth inhibition activity against the in vivo panels of childhood tumors used in the Pediatric Preclinical Testing Program (PPTP). Here we have evaluated rapamycin combined with agents used frequently in the treatment of childhood malignancies. Rapamycin was tested in vitro against 23 cell lines alone or in combination with melphalan, cisplatin, vinc...
متن کاملPediatric Preclinical Testing Program (PPTP) – May 2012
In vitro testing: In vitro testing was performed using DIMSCAN, a semiautomatic fluorescencebased digital image microscopy system that quantifies viable (using fluorescein diacetate [FDA]) cell numbers in tissue culture multiwell plates [1]. Cells were incubated in the presence of drug for 96 hours. Mean fluorescence values were determined for each concentration tested and then normalized to th...
متن کاملPower gain by pre - testing ?
The aim of this paper is to study whether it is possible to gain power by pretesting, and to give insight in when this occurs, to what extent and at which price. A pre-test procedure consists of a preliminary test which tests a particular property of a given restricted model, followed by a main test for the main hypothesis regarding the parameter of interest. After acceptance by the preliminary...
متن کاملUsing Program Slicing Technique to Reduce the Cost of Software Testing
Systems of computers and their application in the lives of modern human beings are vastly expanding. In any kind of computer application, failure in computer systems can lead to a range of financial and mortal losses. Indeed, the major origin of software failure can be located in designing or implementing software. With regard to these statistics, 30% of the software projects have been prospero...
متن کاملThe importance of pre-clinical animal testing in interventional cardiology.
The treatment of cardiovascular disease has changed dramatically over the past 2 decades, allowing patients to live longer and better quality lives. The introduction of new therapies has contributed much to this success. Nowhere has this been more evident than in interventional cardiology, where percutaneous cardiovascular intervention has evolved in the past 2 decades from a quirky experimenta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Blood & Cancer
سال: 2009
ISSN: 1545-5009
DOI: 10.1002/pbc.21976